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INTRACRANIAL ANEURYSM AS A PARADIGM FOR THE GENETIC ANALYSIS
OF COMPLEX HUMAN TRAITS
Ali K. Ozturk, Brian V. Nahed, Kaya Bilguvar, Mohamad Bydon, Fatih Bayrakli, Bulent
Guclu, and Murat Gunel, Department of Neurosurgery, Yale University School of
Medicine, New Haven, Connecticut
The genetic analysis of complex human traits is hampered by its multifactorial
nature, since potentially many genes are imparting a relatively small effect on the disease
trait. This makes it considerably more difficult to identify these genes as compared to
single-gene diseases, whereby the disease trait is attributable to only one locus, due
mostly to the difficulties of carrying out robust linkage analyses.
Several strategies have been employed in order to overcome the obstacles of
complex human traits, including the candidate gene, non-parametric, and parametric
linkage approaches. Of these, the latter two enjoy the benefit of being genome-wide,
while carrying the potential of missing genes that impart slight effect on the disease trait,
a weakness that the candidate gene approach may overcome to some degree.
Our approach to unravel the complex genetics of Intracranial Aneurysms (IA) has
been a blend of the parametric linkage approach, followed by a smaller-scale candidate
gene approach, where genes within a linked interval are sequentially analyzed based on
relevance. We are able to conduct the parametric linkage approach by identifying rare,
outlier families whereby the disease trait is ostensibly being passed on in an identifiable,
Mendelian fashion, enabling us to set the parameters required to perform parametric
linkage analysis.
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Using this method on four of our largest families, we have achieved linkage to
chromosomes 1p34-36, 11q24-25, and 14q23-31 exceeding the statistical threshold of
significance. Importantly, the latter two loci have also been identified in a nonparametric linkage study in Japanese sib-pairs. Anaylsis of genes that lie in these regions
are ongoing.
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INTRODUCTION
The genetic analysis of complex human traits is hampered by locus heterogeneity,
whereby multiple genes may be contributing to a disease trait via small or large effects.
This makes the identification of susceptibility genes considerably more difficult than
single-gene diseases, due to the difficulties of performing robust linkage analyses. The
aim of this work is to consider various approaches to identifying genes leading to
complex traits using intracranial aneurysm (IA) as a paradigm.

Intracranial Aneurysms (IA): Background and Epidemiology
In the United States, nearly 700,000 people suffer from stroke every year (AHA
Stroke Statistics, 2005 Update, http://www.americanheart.org). Subarachnoid
hemorrhage (SAH), one form of hemorrhagic stroke, carries the highest mortality with an
approximately 50% mortality rate one month after the initial bleed (1, 2, 3). Furthermore,
only 25% of those who live past the first month will recover completely, leaving the
majority of survivors requiring a life-time of care (4-6). In the absence of trauma,
intracranial aneurysm (IA) is the primary cause of SAH, accounting for approximately
85% of cases (7). Despite recent advances in diagnostic and therapeutic modalities, the
morbidity and mortality from SAH remains disturbingly high.
IA is surprisingly prevalent; various series have estimated the incidence to be
between 0.2 and 9.9% with a mean of 5% (8). Fortunately, only a fraction of these will
rupture with the majority remaining asymptomatic and discovered only incidentally or
during autopsy. Thus, SAH from IA rupture comprises only 3% of all strokes (5), and
the incidence of SAH remains 6 in 100,000 with 28,000 IA ruptures per year (7). The
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ruptures are, however, devastating when they do occur, and SAH accounts for nearly
25% of all life-years lost due to stroke (9).
While the majority of IA occurs sporadically, familial forms also exist, and they
are being increasingly recognized with recent studies attributing approximately 10% of
all IAs to a genetic predisposition (10). These patients often have two or more firstdegree relative members with IA.
It was once believed that all IAs occurred sporadically. The observation that IA is
associated with known genetic disorders such as Autosomal Dominant Polycystic Kidney
Disease (ADPKD) (11) and Ehlers-Danlos syndrome type IV etc (12), however,
introduced doubt into this observation. Furthermore, these syndromes fall far from
explaining the majority of familial IA cases, defined as two or more relatives with IA.
Familial clustering of IAs has been documented since the 1950’s (13), and the importance
of heritable factors has been increasingly recognized. It is now known that first-degree
relatives of patients with SAH from aneurysm rupture are three to five times more likely
to harbor an IA (14). The relative risk may be even greater in siblings, who have been
reported to have a six-fold higher risk compared to the general population (10).
Familial IA’s behave somewhat differently than sporadic cases. They are prone
to rupture at younger ages, they are more likely to be multiple, and finally, they have a
strong predilection for the middle cerebral artery (MCA) (15-19). With increasing
recognition of familial IA’s as a separate entity, our group, as well as others, has begun
searching for a mutation in a specific gene that specifically causes the formation and
rupture of non-syndromic, inherited IA.
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GENETIC ANALYSIS of COMPLEX TRAITS
Both association (candidate gene) and linkage (parametric and non-parametric)
studies can be used for the genetic analysis of complex traits. In a linkage study, one
investigates the co-segregation of two loci (one of which may be the disease locus) in
families, whereas an association study looks for the co-existence of a disease trait and
genetic polymorphisms. Each has their advantages and disadvantages, and should not be
considered mutually exclusive.

1) Association Studies (Candidate Gene Approach):
In design, association studies are similar to epidemiologic case-control studies,
such that a given trait is compared across allelic variants of a particular DNA marker.
Thus, the frequencies of different allelic variants may be compared in subjects with
particular phenotypes in an attempt to identify a positive association.
Whereas a linkage study is genome-wide, association studies are limited to
candidate genes or regions (20). This is because screening the entire genome would
require too many markers, making it impractical and inefficient. Thus, investigators will
frequently confine themselves to particular genes or regions that they feel have potential
to impart an effect (major or minor) on the disease phenotype. A potential weakness in
this strategy is that it assumes that the disease causing mechanism is one that is already
known, and thus, novel pathways that may be contributing to disease pathophysiology
may be overlooked (20).
Furthermore, while linkage analysis is confined to families or sib-pairs, the
candidate gene approach can be undertaken at a population level, allowing for numerous
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unrelated individuals with the same disease to be analyzed at the same time. While
potentially powerful to detect genes of modest effect contributing to a phenotype (21),
candidate gene approaches are limited by the fact that only a small number of genes can
be studied at one time.
Most candidate genes that consistently have been shown to impart significant
effect on a disease trait has been demonstrated to be functional, that is, they influence the
concentration of a protein, its functionality or efficiency, or its expression patterns (20).
Several strategies have been employed in the past to identify potential candidate genes.
First, if there are genes known to cause a specific disease in animals related to the disease
trait being studied in humans, then the human analogues of those genes may be studied.
Next, genes that take part in certain physiologic mechanisms that are known to be
involved in the disease being studied may be investigated. This approach, as mentioned
earlier, can not identify genes that are part of novel, unstudied pathways. Another
potential weakness emerges here, whereby an overwhelming number of genes may be
identified using these candidate gene finding strategies.
Perhaps the most important and most widely criticized weakness of the candidate
gene approach is the potential for false positive results. In a comprehensive review of
this method, Hirschhorn et al compiled 166 positive association studies that were
analyzed three or more times between single nucleotide polymorphisms and complex
genetic traits (22). Only 6 of the 166 were robust and consistently replicated (22). This
demonstrates an important weakness in the candidate gene approach whereby the more
genes that are analyzed using this strategy, the higher the likelihood of false positive
results. While approaches driven by hypotheses regarding disease mechanisms are
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intuitively attractive, experience has shown repeatedly that genome-wide linkage analysis
is a more fruitful method to isolate causative genes of a complex disorder whose
pathophysiology and molecular biology is not fully established.

2) Linkage Studies:
As previously mentioned, linkage analysis has the benefit of being genome-wide
when compared with association studies. Thus, research is not confined to candidate
genes or regions, and the power to detect proteins that are involved in novel pathways is
much greater using this strategy. Linkage analysis can be carried out in two different
modes: one where the mode of inheritance needs to be specified a priori, called
“parametric” or model-based linkage analysis, and another where the mode of
inheritance, along with other genetic parameters do not need to be specified, so called
“non-parametric linkage analysis.” Traditionally, it has been believed that parametric
linkage analysis is the ideal method for single-gene diseases, in other words diseases
where one gene imparts a major effect on the phenotype. Non-parametric linkage
analysis, on the other hand, has been preferred for the analysis of complex traits with
locus heterogeneity, where several or many genes may be imparting minor effects on the
disease trait.

A) Non-parametric Linkage Analysis:
Non-parametric, or model-free methods were first developed for sibling pairs.
More recently, this method has been extended to general pedigrees (20). As stated
previously, in this method of linkage, no explicit model needs to be specified ahead of
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time for the genome-wide analysis. In non-parametric linkage analysis, many DNA
markers (single nucleotide polymorphisms-SNP’s, or short tandem repeats-STR’s)
dispersed throughout the genome are obtained from siblings, and where possible, from
their parents. Ultimately, allele sharing between affected sibling pairs is investigated and
compared to the expected allele sharing under Mendelian principles. This method is
called the “affected sib-pair” method, since more information lies in the relationship
between two affected siblings than two unaffected siblings (23).
Since no genetic parameters need to be specified with this analysis, nonparametric linkage has been considered the most powerful method for studying complex
traits where identifying a single mode of inheritance (along with other genetic parameters
such as penetrance, phenocopy rate, etc.) may often prove to be difficult. Thus, in theory,
non-parametric methods have the capability to detect multiple loci of minor effect in
polygenic diseases.
This method, however, is not without its weaknesses. First, for the analysis to be
powerful, significant numbers of sib-pairs must be identified and genotyped.
Furthermore, this number that is required to achieve statistical significance will vary
depending on the heritability of the trait. Thus, where 200 sib-pairs may be a sufficient
number for a highly heritable trait, it may prove to be inadequate when searching for loci
with more modest effects. This example illustrates that with non-parametric analyses, it
is still difficult to achieve significance when attempting to detect genes of small effect, or
genes that are affecting only a small proportion of the families being analyzed (20).
Finally, while non-parametric linkage may identify many loci that may be linked to the
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disease trait with varying degrees of significance, the researcher is still left to speculate as
to which of the loci are disease-causing in each individual family.

B) Parametric Linkage Analysis:
Parametric linkage approaches are also referred to as model-based linkage, since
an explicit genetic model (along with all of the genetic parameters) needs to be specified
before the experiments are started. This model is the preferred method when a disease
with a Mendelian mode of inheritance is being studied, and it is hypothesized that a
single gene with a major effect is responsible for causing the phenotype. Typically, in
parametric linkage analysis, one extended family pedigree (as opposed to multiple sibpairs used in non-parametric linkage) will be analyzed. A number of DNA markers (in
the form of SNP’s or STR’s) of known location dispersed throughout the entire human
genome will subsequently be used to investigate the inheritance of portions of the DNA,
statistically computing the recombination frequencies. For each marker, evidence for
linkage is sought using the co-segregation of the trait (and presumably the disease
causing gene) and a particular variant of the marker being analyzed. This is possible
since the closer the two loci (disease locus and marker locus) are located on a
chromosome, the less likely it is that a recombination event will occur between the two,
and the more likely that the specific marker variant will be present in all individuals who
are affected with the disease. Thus the genetic distance between the marker locus and the
disease causing gene can be estimated in centimorgan (cM) units, with 1 cM
corresponding to a recombination fraction of 1% (20).
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Statistically, the LOD score function has added much to parametric linkage
analysis (24). LOD score stands for the logarithm of the odds and is a robust measure of
the strength of the linkage. It is the logarithm of the odds that the DNA marker locus is
linked to the disease trait, and is calculated according to the following formula:

Thus, a LOD score of 3.0 would mean that the probability that two loci are linked
is 1000 times more likely than them being unlinked (on separate chromosomes).
However, any two given loci are approximately 50 times more likely to be unlinked than
linked. Correcting for this factor would mean that the two loci with a LOD score of 3.0
are 1000/50=20 times more likely to be linked than unlinked. This means that there is a 1
in 20 probability that the linkage is due to chance findings, corresponding roughly to a p
value of 0.05. Thus, a LOD score of 3.0 is considered to be the threshold of significance.
Using this approach, the area(s) of the genome with the highest LOD score is
considered to be the most likely to contain the disease causing gene(s). Two methods
may follow the initial genome-wide linkage. First, if the linked region is sufficiently
small one may directly proceed to sequence that portion of the DNA looking for allelic
variants that may directly explain the disease. If the area in question is comparatively
large, one may use STR’s in the region to fine map and look for additional
recombinations that may further refine and shorten the linked interval. This is referred to
as a two-stage design in linkage analysis (25). It is possible, that at the end of both the
initial genome-wide scan and fine mapping using STR’s, the interval is still several
million base pairs long, rendering it unpractical to sequence in its entirety. At this point,
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the researcher may only sequence candidate genes, i.e. those genes in the region that
seem relevant to the disease based on its function, if known, and expression pattern. This
final step may re-introduce the aforementioned risks and potential weaknesses of the
candidate gene approach.
While quite robust in diseases in which a specific inheritance pattern can be
identified, the parametric linkage analysis loses favor for the analysis of complex traits,
due mostly to difficulties in discerning the genetic parameters, i.e. the inheritance mode,
penetrance, phenocopy rate, etc.

Our Approach:
Our approach to unravel the complex genetics of IA formation is a blend of the
previously mentioned approaches, relying most heavily on parametric linkage analysis.
In order to benefit from the robustness of parametric linkage analysis in complex human
traits, one needs to be able to reconcile the need to accurately determine the genetic
parameters, which can prove to be difficult for complex, non-Mendelian inheritance
forms. This can be done with the identification and use of rare, extended kindreds that
are ostensibly passing the trait on from generation to generation in a predictable,
Mendelian manner. Though difficult to find, once identified, these families enable the
use of robust parametric linkage analysis for gene identification while avoiding the
majority of the pitfalls that accompany non-parametric and candidate gene approaches
(26). By restricting our analysis to these rare, “outlier” families, we are, in essence,
converting the complex trait of intracranial aneurysm into a simple, single-gene disease.
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In an attempt to recruit such large, multi-generational IA families, the Gunel lab
has, over the past 10 years, screened over 3200 IA patients and identified 168 IA
kindreds, with are a total of more than 450 affected patients. Critically, four of these
families are sufficiently large to support genome-wide linkage independently (IA 20, 42,
100, and 101).
Having identified and recruited these families, our approach is that of a two-stage
design in linkage analysis. First, we use Affymetrix gene chips that utilize 10,000 SNPs
dispersed relatively evenly throughout the human genome on all of the affected members
of the kindred. This initial, affected-only analysis, is the most dependable and accurate,
demonstrating the areas of the genome that are shared by all individuals with IA. In this
phase, the pre-defined penetrance rate is not an issue, since unaffected members that may
be inheriting the high-risk portion of the genome that may not be phenotypically affected
are excluded. Following the initial genome-wide scan of affected members, we genotype
all candidate loci that give a theoretical maximum LOD score using STR’s that span the
candidate loci. At the end of this second phase, our goal is to be left with one candidate
interval that is demonstrating maximum LOD score with all individuals included, both
affected and unaffected. This second stage of genetic analysis using STR markers also
has the added benefit of potentially narrowing and refining the locus at hand, presumably
minimizing the amount of DNA needing to be directly sequenced while looking for
allelic variations (26).
As mentioned previously, if, after this two-stage approach to linkage analysis we
are still left with a region spanning millions of base pairs precluding direct sequencing of
the entire region, we proceed to take a pseudo-candidate gene approach, identifying the
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genes that lie within the region and sequencing directly those which we feel may have a
role in aneurysm pathogenesis, based on function and expression pattern. Identification
of a frameshift mutations or a stop codon resulting in a truncated protein is considered
strong evidence in favor of disease-causing potential. If, on the other hand, a point
mutation leading to an amino acid change is noted, then this change needs to be analyzed
more aggressively with the use of additional patients with IA, and control patients.
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STATEMENT OF PURPOSE
We hypothesize that a single-gene defect may be identified in rare, outlier
families with IA which leads directly to the disease phenotype. While identification of
such families is difficult, they enable the use of parametric linkage approaches, since the
mode of inheritance can be identified. We believe that parametric linkage approaches, in
such outlier families, are more robust than the non-parametric or candidate gene
approaches.
Identification of a gene that directly leads to IA phenotype in the aforementioned
families can subsequently be analyzed in other forms of familial IA, as well as sporadic
ones, to investigate whether the protein product of the identified gene plays any role in
rare, and more common forms of the disease.
Finally, the protein product of the identified gene will help elucidate the
pathophysiological mechanisms leading to IA, and may even result in a screening test
that could detect IA before they rupture.
All presented work was performed by Ali K. Ozturk, with the exception of the
linkage analysis of IA 20, which was performed by Brian V. Nahed.
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METHODS
Collection of blood samples and Isolation of Genomic DNA
After HIPAA and HIC (Yale HIC#7680) consents were obtained, blood samples
were collected from affected subjects and, where possible, from all members of the family
regardless of affection status. Total genomic DNA was prepared by isolation of nuclei
followed by proteinase K - SDS lysis and subsequent phenol and chloroform extractions
(26).

Phenotype assignment of family members
All phenotypes were assigned prospectively. Affected status was assigned after
confirmation of the presence of an IA based on MRA, CTA, or conventional angiogram.
In cases where the diagnostic imaging studies were performed at outside institutions, we
obtained original images whenever possible; these images were blindly read by a senior
interventional radiologist at Yale who then assigned the phenotype status. Otherwise,
medical records including the official dictation of the diagnostic studies were obtained. At
risk individuals with no symptoms who are <30 years of age were classified as phenotype
unknown, as were members with aneurysms of the aorta or other extracranial vessels (26).
All other members were designated unaffected phenotype.

SNP genotyping:
We used the GeneChip Mapping 10K Xba Array containing 10,044 SNP markers
(Affymetrix: Santa Clara, CA) for genome wide linkage analysis. SNP genotypes were
obtained by following the Affymetrix protocol for the GeneChip Mapping 10K Xba
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Array. Briefly, genomic DNA was digested with XbaI; adapters were ligated to the
product and an adapter-specific primer was used to amplify the product by PCR. The
products were purified, fragmented and labeled with biotin-ddnTP. Biotin-labeled DNA
fragments were hybridized to the mapping 10K array chip. After hybridization, arrays
were washed, stained, and scanned. Affymetrix MicroArray Suite 5.0 software was used
to obtain raw microarray feature intensities which were processed using the Affymetrix
Genotyping Tools software package to derive SNP genotypes.
An average of 9468 genotypes was scored per subject (SNP call rate range: 91% –
97%). To analyze the Genechip data for linkage we created a UNIX based program
(Chunky) that parses the data sheet into individual files per chromosome in linkage
format. Information captured includes chromosome number, SNP markers, map
distances, genotype calls, and allele frequencies.
We performed multipoint analysis of linkage, specifying the disease locus as
autosomal dominant with penetrance varying from 70 to 99%, a mutant disease gene
frequency of 0.001, and a phenocopy rate of 0.001. SNP allele frequency data for the
Caucasian population, as supplied by Affymetrix, was used for the analysis of linkage
which was performed using the Allegro program (DeCode Genetics, Iceland).

Confirmation of Linkage Using Microsatellite Short Tandem Repeat (STR) Markers:
Suggestive genomic regions were identified using the above approach. Regions
with lod scores close to the theoretical maximum were identified and microsatellite short
tandem repeat (STR) markers were then found within these regions by using the physical
map data from the UCSC Genome Browser (May 2004, http://genome.ucsc.edu). All
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members of the family, both affected and unaffected, were genotyped. This strategy is
often referred to as a two-stage design in linkage analysis. All genotyping for
microsatellite analysis was performed by polymerase chain reaction, with detection of
fluorescent products on an ABI 3700 sequencer from Applied Biosystems equipped with
Genescan and Genotyper software (ABI, Norwalk, CT). The results were analyzed using
the SimWalk2 program (http://www.genetics.ucla.edu/software/simwalk2) with
penetrances specified between 70 and 99%.

Mutational Analysis:
As a first step, we have already determined the transcripts located in each of the
intervals. Even though we mainly rely on the Genome Browser (May 2004 version) of
the University of California, Santa Cruz (UCSC) website (http://genome.ucsc.edu), we
use a number of other databases to search for additional transcripts in the linked intervals.
These databases include the Mapview of the NCBI
(http://www.ncbi.nlm.nih.gov/mapview/) and the Ensembl website
(http://www.ensembl.org).
Among the genes located in a linked interval, we prioritize transcripts for further
study based on known function and/or expression patterns. These data are obtained
through both the Affymetrix expression data available at the UCSC genome browser as
well as via data-mining of the PubMed database. For example, genes that are expressed in
vascular structures, especially arteries, such as those expressed by vascular smooth
muscle cells, endothelium, or those that are abundant in the brain along with extracellular
matrix (ECM) genes are viewed as likely candidates.
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The genomic sequence of these genes along with the exon/intron boundaries that
are determined using the above programs are downloaded to the Sequencher program.
The primers for PCR amplification of the exons are designed using PRIMER3
(http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi) and the coding regions of the
gene of interest are amplified and sent for direct sequencing. Given the relatively small
number of samples to evaluate, we prefer direct sequencing to other mutation screening
technologies as it is the most sensitive and reliable method.
For large families that show exclusive linkage to a locus, we will sequence the
index case and another affected member to determine if an identified polymorphism
segregates among the affected members. If a polymorphism is found to be present in both
of these two patients, we then sequence additional affected and unaffected members to
test whether the observed polymorphism segregates with the IA phenotype. We also
check the available databases to see if this polymorphism is a previously reported SNP. A
polymorphism segregating on the affected chromosome that leads to a stop codon or a
frameshift mutation is considered highly likely to be the disease causing mutation.
Any other polymorphism on the affected chromosome that is not reported in the
SNP databases (http://www.ncbi.nlm.nih.gov/projects/SNP/) is investigated in control
chromosomes. The identification of a rare, segregating mutation in an affected family but
not in several thousand controls, in conjunction with the relevant expression data, will
strongly implicate mutations in a particular gene in the pathogenesis of IA.
The same gene is then tested for mutations in additional IA families that link to
the respective IA locus and familial IA cases without any linkage information, along with
250 sporadic IA cases, in an effort to identify additional mutations in the same gene. For
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this stage, we rely on a two-stage strategy of temperature gradient column electrophoresis
with a Spectrumedix REVEAL system followed by direct sequencing on both strands of
putative heteroduplexes to identify any additional mutation. Identification of additional
mutations will strongly support the hypothesis that the disease causing gene is identified.

22

RESULTS
Parametric Linkage Analysis in IA:
As mentioned previously, four of our 168 IA families were large enough to
support linkage independently, and we have finished the majority of the analysis. The
following are the results from the genome-wide linkage studies performed on these
families.

1) IA 20:
Epidemiology:
This family is originally from West Virginia. In 1980, Fox and Ko (27) reported
this family as being the largest reported IA kindred with six affected members, at the
time, all of whom were in generation II. Since then, we have recruited this family for our
study, and extended the pedigree to include ten documented IAs, one subject with
distinctive multiple intracranial vessel occlusions and extensive collateral vessel
formation of unknown etiology (subject III-3), and one subject with abdominal aortic
aneurysm (AAA) at a young age (age 32; individual II-5); this latter trait is sometimes
associated with IA (Figure 1A).
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Figure 1A. IA 20 kindred. Affected and unaffected individuals are shown as filled
and unfilled symbols, respectively. Obligate carriers are shown as partially filled
symbols. Individual II-5 was assigned affection status unknown prior to linkage
analysis and is shown as a grey symbol.

During our phenotypic assignment, we prospectively designated the family
member with vessel occlusions as being affected, and the member with an AAA as being
phenotype unknown. All subjects that were asymptomatic, over the age of 30, and had
negative screening studies were designated as unaffected (individuals II-3, II-6, II-11, II14, III-1, III-2, III-8, IV-2), while those under the age of 30 were assigned an unknown
phenotype (individual IV-1). Finally, those subjects without screening studies who were
over age 30 and asymptomatic were also designated unaffected (individuals III-4, III-9,
III-10). The aneurysm characteristics and age at diagnosis are shown in Table 1A.
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Table 1A: Clinical features of affected members of kindred IA 20

ID
II-1
II-7
II-9
II-15
III-3
III-7
IV-3

Aneurysm Location
AcoA
ACA, Lt MCA
AcoA
Lt MCA
Bilateral MCA occlusion
Lt MCA
Basilar, Rt MCA X 2

Age of
diagnosis
38
53
40
29
30
36
21

* ACA: anterior cerebral, ACoA: anterior communicating, MCA: middle cerebral artery.

Linkage Analysis:
As a first step, we performed an affected only analysis using the six affected
members of this family with Affymetrix genechips and the Allegro program as previously
described (see Methods section). This analysis led to three peaks throughout the human
genome with a LOD score at or near the theoretical maximum expected for this family.
These candidate regions were located at 1p34 – 1p36, 1q31 – 1q41, and 2p11 – 2p14, all
of which resulted in a LOD score of approximately 1.5 (Figure 1B). Following this, we
genotyped all members of the family, both affected, unaffected, and unknown with STR
markers spanning the three candidate loci to see which of the three loci were most likely
to contain the disease-causing gene. Following this analysis, the locus on chromosome
1p34-36 demonstrated a LOD score of 4.2 specifying a penetrance of 99% (Figure 1C),
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Figure 1B. Analysis of linkage in IA 20 from GeneChip data of affected individuals.
Linkage graphs for all chromosomes are shown; x-axis corresponds to genetic
distance (cM) and y-axis shows lod scores.
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while the LOD scores on the remaining two loci diminished significantly (Table 1B). Of
note, if family member III-3, with bilateral MCA artery occlusions is designated as
phenotype unknown, the maximum LOD score at 1p34-36 diminishes to 3.9 with no
significant effect on chromosomal location (26).
Figure 1C. Analysis of linkage with STR markers on 1p34-36 localizes an IA gene to
a 12.5 cM region between markers D1S199 and UT5144 with a maximum lod score
of 4.2. Multipoint analysis of linkage comparing segregation of IA and marker loci
was performed. The location of marker loci used is indicated at the top of the
diagram. The horizontal bar indicates the extent of the lod-1 interval.
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Table 1B: Maximum lod scores for linkage of STRs and IA

Interval
1p34 – 1p36
1q31 – 1q41
2p11 – 2p14

70%
3.4
1.3
-0.3

Penetrance
90%
3.9
-0.1
-2.3

99%
4.2
-5.6
-6.6

Maximum lod scores are reported for 1p34 – 1p36, 1q31 – 1q41, and 2p11 – 2p14 using
STR markers in all family members with varying estimates of penetrance (Table 1B).
We thus concluded that a gene located on 1p34-36 was the cause of IA in this family.
There are approximately 240 genes located within this interval spanning nearly 14
million base pairs (bp). As stated previously, this is too many to allow for direct
sequencing of the entire region. We have thus taken a candidate gene approach within
the linked interval, specifying genes that were more likely to be associated with IA based
on function and expression pattern, and sequencing them first. We only sequence coding
exons, introducing room for error in the event of a genetic abnormality located within
non-coding exons, or intronic sequenes. However, to sequence whole genes is, with
current technology, impractical and unfeasible.
Using this approach, we have sequenced nearly 60 genes located within this
interval, including Brain-Specific Angiogenesis Inhibitor (BAI), Collagen Type XVI,
alpha1 (COL16A1), and Heparan Sulfate Proteoglycan 2. While we have identified
numerous polymorphisms in these genes, none of them co-segregated with the trait, and

29

we have identified no allelic variation that could potentially cause IA in this family.
Sequencing of additional genes is ongoing.

2) IA 100
Epidemiology:
This family is originally from Columbia, but several members, including the index
case, reside in the United States. The index case (III-7, Fig. 2A), works frequently with
the PI, and upon mentioning her extensive family history, was screened and found to
have an unruptured 8mm anterior communicating artery IA. She later underwent
successful clipping of her aneurysm by the PI and became an advocate for genetic
studies. The rest of her family lives in Colombia and with her help, screening MRA or
CTA studies were performed and samples were collected. Results of the imaging studies
identified three other affected members of her family (III-9, III-16, and III-17) (Fig. 2A).
Members III-3 and III-9 were both found to have mild a fusiform dilation of the
cavernous segment of the internal carotid artery based on MRA and were therefore
prospectively designated as phenotype unknown (grey symbols in Fig. 2A). Furthermore,
two subjects, II-2 and III-4, have documented AAAs (Fig. 2A). The characteristics of the
family are presented in Table 2.
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Figure 2A. IA 100. Affected and unaffected individuals are shown as filled and
unfilled symbols, respectively. Individuals II-2 and III-4 were assigned affection
status unknown prior to linkage analysis and are shown as grey symbols.

Table 2
Clinical Features of Affected Members in ICA 100

ID

Aneurysm Location and Size

SAH

Age at Diagnosis
(years)

III-7

AComA, 8mm

-

40

III-9

ACA, A2/3 junction, 4mm

-

56

III-16

MCA

-

57

III-17

Right MCA bifurcation, 3-4 mm

-

54

a

AComA, anterior communicating artery; ACA, anterior cerebral artery;

MCA; middle cerebral artery.

Linkage Analysis:
Affected only analysis on the four family members with documented IAs
demonstrated theoretical maximum linkage on multiple chromosomes throughout the
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genome (Figure 2B). We performed linkage under two models: 1) we considered
individuals II-2 and III-4 who are known to harbor AAAs as affection status unknown; 2)
we considered them as affected.
Due to limitations in the genechip software, we were only able analyze seven
family members at one time. Using this method, we first added unaffected family
members III-5, 10, and 15 to the four affected individuals in all of the chromosomes
which yielded a theoretical maximum lod score in the affected only linkage analysis.
Only the loci on chromosomes 3, 6, 11, and 17 (Figure 2C) continued to demonstrate
linkage. Subsequently, we added three different unaffected individuals (III-2, 8, and 12)
to our four affecteds in these four chromosomes, and found that only the locus on
chromosome 11 remained while the other three loci showed significantly diminished
evidence of linkage (Figure 2D). Finally, the locus on chromosome 11 is also the only
one to be inherited by individuals II-2 and III-4 under the model that mutations in the
same gene are causing their AAAs. Further genotyping of all unaffected individuals
revealed a maximum lod score of 4.3 on chromosome 11q specifying a penetrance of
99% if individuals with AAAs (II-2 and III-4) are considered as affected. Assigning an
affection status unknown phenotype to these two individuals gives a lod score of 3.6
without any effect on the chromosomal localization. The lod-1 interval for the IA 100
locus lies between 125.6 to 131.4 million base pairs (mbp) on chromosome 11q24-25,
between SNP markers rs618176 and rs1940033. Interestingly, this is one of the 14
regions linking to IA in a Japanese sib pair study, demonstrating a statistically significant
linkage (p=0.023) between marker D11S910, located at 131.2 mbp on 11q, and the IA
phenotype.
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Figure 2B. Analysis of linkage in IA 100 from GeneChip data of affected
individuals. Linkage graphs for all chromosomes are shown; x-axis corresponds to
genetic distance (cM) and y-axis shows lod scores.
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Figure 2C. Analysis of linkage in IA 100 from GeneChip data of affected and
unaffected individuals. Linkage graphs for all chromosomes are shown; x-axis
corresponds to genetic distance (cM) and y-axis shows lod scores.

34

Furthermore, the markers immediately centromeric and telomeric to D11S910 that did
not show significant linkage with IA (p>0.05) are D11S4151 and D11S4125, located at
125.8 and 133.7 mbps, respectively. This suggests that the longest interval that can
contain an IA susceptibility gene on 11q is between 125.8 to 133.7 mbp. Thus, the IA 100
locus that lies between 125.6 to 131.4 mbp is almost fully contained within the region
defined by the Japanese study.

Figure 2D. Analysis of linkage in IA 100 from GeneChip data of affected and
unaffected individuals. Linkage graphs for all chromosomes are shown; x-axis
corresponds to genetic distance (cM) and y-axis shows lod scores.
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Sequencing of the genes located within this interval is ongoing. Thus far, we were able to
identify no conclusive polymorphism that appears to be directly leading to IA in this
family (Ozturk, 2006).

3) IA 101
Epidemiology:
This kindred was identified in Los Angeles. There are a total of 9 members with
documented IAs, 4 of whom are deceased and one of whom refused to provide a blood
sample (IV-5) (Figure 3A). We thus collected samples from four affected individuals. In
addition, samples from 24 unaffected members were collected. The aneurysm
characteristics in this family are presented in Table 3.

Figure 3A. IA 101. Affected and unaffected individuals are shown as filled and
unfilled symbols, respectively. Individual V-2 was assigned affection status
unknown prior to linkage analysis and is shown as grey symbol.
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Table 3
Clinical Features of Affected Members in ICA 101

ID

Aneurysm Location and Size

SAH

Age at Diagnosis
(years)

IV-1

AComA

-

41

IV-4

MCA

-

42

IV-7

AComA

-

57

IV-9

ACA

-

59

a

AComA, anterior communicating artery; ACA, anterior cerebral artery;

MCA; middle cerebral artery.

Linkage Analysis:
Affected-only genome wide linkage analysis revealed suggestive linkage to
various regions (Figure 3B). Additional GeneChip analysis of 7 unaffected members
(individuals III-4, IV-2, IV-5, IV-8, IV-10, V-1, and V-3), all with negative imaging
studies, revealed linkage to chromosomes 3 and 14, both with a maximum lod score of 3.0
at 99% penetrance. We then identified highly polymorphic microsatellite markers in both
of these regions and genotyped all of the kindred members. This analysis showed that the
locus on chromosome 14 is 100 times more likely to harbor an IA susceptibility gene than
the locus on chromosome 3 (Figure 3C).
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Figure 3B. Analysis of linkage in IA 101 from GeneChip data of affected
individuals. Linkage graphs for all chromosomes are shown; x-axis corresponds to
genetic distance (cM) and y-axis shows lod scores.
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The lod-1 interval is located between SNP markers rs2359991and rs2373098
which are at 75.5 and 85.6 mbp, respectively, on 14q23-31. Similar to the IA 100 locus,
two markers located within the IA 101 locus were found to have statistically significant
linkage with the IA phenotype in the Japanese study. Markers D14S74 and D14S258,
located at 77.7 and 77.8 mbp, showed highly significant linkage to IA (p=0.003 and 0.034,
respectively). This study suggested an IA susceptibility locus between 63.6 to 87.6 mbp
based on the location of the two surrounding markers, D14S63 and D14S68, with no
significant linkage to IA (p>0.05). Thus the overlap between the suggestive intervals in
the two studies is between 75.5 to 85.6 mbp on chromosome 14q (Ozturk, 2006).
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Figure 3C. Analysis of linkage in IA 101 from GeneChip data of affected and
unaffected individuals. Linkage graphs for all chromosomes are shown; x-axis
corresponds to genetic distance (cM) and y-axis shows lod scores.
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4) IA 42
Epidemiology:
This family was recently identified in Pennsylvania. Currently, there are a total of
five living affected members, four of whom are siblings; the fifth is their cousin (Figure
4A). There are also three deceased members with reported IAs. Furthermore, we have
collected blood samples from 25 unaffected individuals in the family. Aneurysm
characteristics of this family are shown in Table 4.

Figure 4A. IA 42. Affected and unaffected individuals are shown as filled and
unfilled symbols, respectively. Family members with negative imaging studies are
designated with an “N”.
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Table 4
Clinical Features of Affected Members in ICA 42

ID

Aneurysm Location and Size

SAH

Age at Diagnosis
(years)

III-1

AComA

+

III-2

MCA

+

56

III-3

MCA

+

57

III-4

MCA, ACA

-

38

III-16

AComA

+

54

a

40

AComA, anterior communicating artery; ACA, anterior cerebral artery;

MCA; middle cerebral artery.

Linkage Analysis:
While genetic linkage analysis of this family is not complete, we have performed
an affected only analysis of the five members with IA. Initial linkage studies
demonstrated robust linkage to chromosomes 7, 10, 12, 16, 18, and 19 (Figure 4B). In
order to narrow down these candidates to only one interval, we will use unaffected
members of the family, as described previously, but also will rely on the MRA results of
the five family members who are currently being evaluated for the presence of an IA.
The addition of one or more affected members to this family will also narrow the
candidate intervals, while avoiding the complications of incomplete penetrance.
Seemingly unaffected individuals, on the other hand, who inherit the high-risk portion of
the genome, make the analysis more difficult to interpret by lowering the LOD score in
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the disease gene-containing region. It is for this reason that when possible, we prefer the
affected only analysis as the most reliable and robust in linkage analysis.

Figure 4B. Analysis of linkage in IA 42 from GeneChip data of affected individuals.
Linkage graphs for all chromosomes are shown; x-axis corresponds to genetic
distance (cM) and y-axis shows lod scores.
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DISCUSSION
Linkage and association studies are not without their inherent strengths and
weaknesses. While linkage is more thorough, inasmuch as it takes into account the entire
genome, it may fail to detect genes imparting small effects on the disease trait.
Association studies, on the other hand, rely on pathways of disease that have already been
identified, and are not good tools to decipher novel pathways leading to disease. Given
these strengths and shortcomings of association and linkage studies (both parametric and
non-parametric), research needs to focus on employing them as best as possible to benefit
from their strengths while avoiding the pitfalls inherent in all of the mentioned
approaches. These methods, thus, should not be thought of mutually exclusive, but rather
accepted as being fully compatible with one another, and used in a complementary way.
Thus, association studies may be performed after an initial genome-wide scan, limiting
the room for error introduced with this method, and also, presumably, limiting the
number of genes needing to be directly sequenced.
The challenge, then, is accomplishing a robust linkage analysis at or above
statistical significance. In the setting of substantial locus heterogeneity, as is the case
with all complex human traits including IA, this is no small feat. The identification of
rare families, who are ostensibly inheriting the disease trait in a simple Mendelian
fashion, circumvents this obstacle. While difficult to find, such rare, extended families
reduce the complex trait into one that is caused by a single gene imparting a large effect
on the disease trait, and by so doing, enable the use of parametric linkage approaches.
The gene that is causing the disease in the outlier family, if identified, may subsequently
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be analyzed in other, more common, forms of the disease to determine any, if not more
subtle, roles the gene may have in these seemingly sporadic cases.

Genetics of Intracranial Aneurysm:
Multiple lines of evidence suggest that genetic factors are involved in IA
formation. The existence of families with multiple members with IA has been known for
some time. In the 1960’s Ulrich and Sugar reported four families with two or more
siblings affected by IAs. In the 1970’s Brisman et al reported families with an autosomal
dominant inheritance of intracranial aneurysms (28). In 1983, Fox and Ko reported the
largest kindred at the time in which 6 of 13 siblings were found to harbor IAs (27). It is
now known that first degree relatives of affected individuals have a three to five-fold
increase in risk compared to the general population (14).
In light of these developments, several groups have begun to search for genes that
may directly lead to IA phenotype in select families. Various groups have used all of the
above approaches to identify an IA gene with only limited success.
Several candidate genes have been implicated in the pathogenesis of IA but have
yet to display a causal relationship. These genes range from those associated with
vascular wall formation to those that are mutated in connective tissue disorders and
include Elastin, Collagen III, Fibrillin, Polycystin, and Endoglin (12, 29-40). Despite
several loose associations identified with a few of these genes and the IA trait, none of
these associations have been consistently reproducible, leaving many in doubt in terms of
the effectiveness of the candidate gene approach with regards to IA. While approaches
driven by hypotheses regarding disease mechanisms, such as candidate gene mutational
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analysis are intuitively attractive, experience has shown time and time again that
positional cloning is the most productive method for isolating causative genes when the
pathophysiology and molecular biology of a disorder is not well elaborated.
Overall, non-parametric linkage analyses have identified multiple loci that may be
contributing to IA on several chromosomes including 5q22-31(41-43), 17cen (44), 19q
(44, 45) and Xp (44). The strongest evidence to date implicates regions on chromosomes
7q and 19q, both of which have been suggested to contain an IA locus in independent
studies.
Although non-parametric approaches are attractive with respect to IA as they are
robust in the face of misspecification of inheritance and do not rely on recruitment of
multigenerational families, an alternative strategy to gene discovery in complex genetic
disorders, including IA, involves the use of traditional parametric linkage analysis in
unusual families. By confining analyses to a single or a few large families that appear to
demonstrate simple Mendelian inheritance, one minimizes the chance of obscuring linkage
due to genetic heterogeneity or environmental factors. This approach has been successful
in identifying rare mutations imparting large effects on blood pressure, lipid metabolism,
insulin resistance, and obesity, leading to a better understanding of the molecular
pathophysiology of these traits. In these and other conditions, the study of outlier families
affected with Mendelian forms of the disease have had a major scientific impact by
providing a launching point for investigations aimed at elucidating relevant
pathophysiological mechanisms. While there have been fewer studies utilizing this
approach in IA, the preliminary results have been quite promising: a recent report by Roos
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et al identified an IA locus on 2p13 by studying a consanguineous Dutch family with a
maximum lod score of 3.55 linking IA to a 7 cM region containing 150 genes (46).
By using an outlier approach that relies on parametric linkage studies in large
families, our group has already reported an IA susceptibility locus on 1p34-36 with a
maximum lod score of 4.2. More recently, we have used the same approach on two other
large families and have identified two more loci on 11q and 14q. In all these studies,
during the second stage of linkage analysis, we genotyped all individuals—affected and
unaffected—to confirm or exclude candidate loci identified during the first stage of
linkage. Since affected plus unaffected analysis is not as reliable as affected only analysis,
we took several measures to ensure accuracy: we screened all the at risk individuals with
imaging studies and accounted for age-dependent penetrance by not including any
individual younger than 30 years of age in our linkage analysis. Furthermore, the intervals
identified in these two families are among the 14 regions reported to show significant
linkage to IA in another study by Onda et al. that reported genome-wide linkage of 104
Japanese affected sib-pairs using 404 polymorphic markers throughout the human genome
(41). The confirmation of these loci by another group in a separate population using a
different approach is strong evidence in favor of the veracity of the results.
Identification of IA susceptibility loci is the first step in the positional cloning of
IA genes. This will be followed by mutational analysis of candidate genes in these
intervals which eventually will lead to the cloning of IA genes. The identification of
responsible proteins that cause aneurysms is an important first step in the development of
new therapeutic approaches to this devastating disease.
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